Cargando…
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) showed efficacy in metastatic colorectal cancer (mCRC) with mismatch-repair deficiency or high microsatellite instability (dMMR-MSI-H). Unfortunately, a patient’s subgroup did not benefit from immunotherapy. Caudal-related homeobox transcription factor 2 (CDX-2) w...
Autores principales: | Ziranu, Pina, Pretta, Andrea, Pozzari, Marta, Maccioni, Antonio, Badiali, Manuela, Fanni, Daniela, Lai, Eleonora, Donisi, Clelia, Persano, Mara, Gerosa, Clara, Puzzoni, Marco, Bardanzellu, Fabio, Ambu, Rossano, Pusceddu, Valeria, Dubois, Marco, Cerrone, Giulia, Migliari, Marco, Murgia, Sara, Spanu, Dario, Pretta, Gianluca, Aimola, Valentina, Balconi, Francesca, Murru, Stefania, Faa, Gavino, Scartozzi, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020482/ https://www.ncbi.nlm.nih.gov/pubmed/36928082 http://dx.doi.org/10.1038/s41598-023-31538-3 |
Ejemplares similares
-
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression
por: Ziranu, Pina, et al.
Publicado: (2023) -
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
por: Spanu, Dario, et al.
Publicado: (2022) -
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?
por: Pretta, Andrea, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021) -
How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022)